Featured Publications
Women with PCOS who undergo IVF: a comprehensive review of therapeutic strategies for successful outcomes
Kotlyar A, Seifer D. Women with PCOS who undergo IVF: a comprehensive review of therapeutic strategies for successful outcomes. Reproductive Biology And Endocrinology 2023, 21: 70. PMID: 37528417, PMCID: PMC10391774, DOI: 10.1186/s12958-023-01120-7.Peer-Reviewed Original ResearchConceptsPolycystic ovarian syndromeOvarian hyperstimulation syndromeOvarian stimulationStimulation protocolFrozen embryo transfer cyclesVitamin D repletionGnRH agonist triggerVitamin D levelsEmbryo transfer cyclesOvarian stimulation protocolsAntagonist cyclesHyperstimulation syndromeHypertensive disordersIVF cyclesPCOS patientsAgonist triggerOvarian syndromeOocyte yieldD levelsImproved outcomesPregnancy rateCommon causeIVF performanceTherapeutic courseInfertile couples
2022
Evaluation of the Association of Endometrial Thickness, Insulin Resistance, and Menstrual Patterns in Adolescent Females with Polycystic Ovarian Syndrome
Lynn A, Solomon N, Zamani M, Rowe E, Seifer D, Vash-Margita A. Evaluation of the Association of Endometrial Thickness, Insulin Resistance, and Menstrual Patterns in Adolescent Females with Polycystic Ovarian Syndrome. Journal Of Pediatric And Adolescent Gynecology 2022, 36: 134-139. PMID: 36403727, DOI: 10.1016/j.jpag.2022.11.005.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBody Mass IndexCase-Control StudiesChildFemaleHumansInsulin ResistancePolycystic Ovary SyndromeRetrospective StudiesYoung AdultConceptsPCOS groupInsulin resistanceMenstrual patternAdolescent femalesControl groupRetrospective case-control studyLarge-scale prospective studiesAcute pelvic painEndometrial stripe thicknessTransabdominal pelvic ultrasoundTertiary children's hospitalPolycystic ovarian syndromeBody mass indexCase-control studyInstitutional review boardAdolescent PCOSEndometrial thicknessPelvic painOvarian syndromePCOS diagnosisPelvic ultrasoundUnique pathophysiologyEndocrinology clinicChildren's HospitalMass index
2020
The association between anti-Müllerian hormone and vitamin 25(OH)D serum levels and polycystic ovarian syndrome in adolescent females
Simpson S, Seifer DB, Shabanova V, Lynn AY, Howe C, Rowe E, Caprio S, Vash-Margita A. The association between anti-Müllerian hormone and vitamin 25(OH)D serum levels and polycystic ovarian syndrome in adolescent females. Reproductive Biology And Endocrinology 2020, 18: 118. PMID: 33218348, PMCID: PMC7679991, DOI: 10.1186/s12958-020-00676-y.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAnti-Mullerian HormoneFemaleHumansPolycystic Ovary SyndromeRegression AnalysisRetrospective StudiesRisk FactorsVitamin DYoung AdultConceptsPolycystic ovarian syndromeRotterdam diagnostic criteriaNon-PCOS groupMedian AMHOvarian syndromePCOS groupDiagnostic criteriaAnti-Müllerian hormone levelsAdolescent femalesRetrospective chart reviewTraditional clinical markersAnti-Müllerian hormoneCross-sectional studyWilcoxon rank sum testSignificant unadjusted differencesRank sum testD deficiencyChart reviewClinical featuresEndocrinology clinicSerum levelsAdjusted analysisUnadjusted comparisonsInsurance typeSurrogate markerAnti-Müllerian hormone as a qualitative marker - or just quantity?
Kotlyar A, Seifer DB. Anti-Müllerian hormone as a qualitative marker - or just quantity? Current Opinion In Obstetrics & Gynecology 2020, 32: 219-226. PMID: 32205525, DOI: 10.1097/gco.0000000000000623.Peer-Reviewed Original ResearchMeSH KeywordsAbortion, SpontaneousAnti-Mullerian HormoneBiomarkersFemaleFertilization in VitroHumansOocytesOvarian ReservePolycystic Ovary SyndromePregnancyPrimary Ovarian InsufficiencyConceptsAnti-Müllerian hormoneOvarian reserve testingClinical pregnancy rateLive birth rateOnset of menopausePremature ovarian insufficiencyNumber of oocytesSignificant predictive valueAMH levelsFertilization cyclesPregnancy rateOvarian insufficiencyIntracycle variabilityOocyte qualityPredictive valueEarly folliclesFetal trisomiesHormoneReproductive technologiesRiskQualitative markersSmall interMenopauseInsufficiencyFolliclesHigh serum Antimullerian hormone levels are associated with lower live birth rates in women with polycystic ovarian syndrome undergoing assisted reproductive technology
Tal R, Seifer CM, Khanimov M, Seifer DB, Tal O. High serum Antimullerian hormone levels are associated with lower live birth rates in women with polycystic ovarian syndrome undergoing assisted reproductive technology. Reproductive Biology And Endocrinology 2020, 18: 20. PMID: 32156287, PMCID: PMC7065318, DOI: 10.1186/s12958-020-00581-4.Peer-Reviewed Original ResearchConceptsLive birth rateLower live birth ratesHigh AMH groupAMH groupPCOS womenHigh AMHAMH concentrationsFirst fresh IVF/ICSI cycleBirth rateFresh IVF/ICSI cyclesGreater clinical pregnancy ratesSerum antimullerian hormone (AMH) levelsIVF/ICSI cyclesAntimullerian hormone levelsClinical pregnancy rateControlled ovarian stimulationRetrospective cohort studySerum AMH levelsPolycystic ovarian syndromeSerum AMH concentrationsLive birth outcomesNumber of embryosAMH levelsGonadotropin doseOvarian stimulation
2018
Vitamin D Deficiency Is Associated With Poor Ovarian Stimulation Outcome in PCOS but Not Unexplained Infertility
Butts SF, Seifer DB, Koelper N, Senapati S, Sammel MD, Hoofnagle AN, Kelly A, Krawetz SA, Santoro N, Zhang H, Diamond MP, Legro RS, Network E. Vitamin D Deficiency Is Associated With Poor Ovarian Stimulation Outcome in PCOS but Not Unexplained Infertility. The Journal Of Clinical Endocrinology & Metabolism 2018, 104: 369-378. PMID: 30085176, PMCID: PMC6300410, DOI: 10.1210/jc.2018-00750.Peer-Reviewed Original ResearchConceptsVitamin D deficiencyPolycystic ovary syndromeD deficiencyEarly pregnancy lossOvarian stimulationUnexplained infertilityLive birthsPregnancy lossDiagnosis of PCOSMultiple Intrauterine GestationsOvarian stimulation outcomesRetrospective cohort studyInvestigation of womenBanked seraPPCOS IICohort studyIntrauterine gestationOvary syndromeInfertile womenInfertility diagnosisPregnant subjectsElevated riskImportant treatmentReproductive outcomesTrial data
2017
Potential therapeutic applications of human anti-Müllerian hormone (AMH) analogues in reproductive medicine
Kushnir VA, Seifer DB, Barad DH, Sen A, Gleicher N. Potential therapeutic applications of human anti-Müllerian hormone (AMH) analogues in reproductive medicine. Journal Of Assisted Reproduction And Genetics 2017, 34: 1105-1113. PMID: 28643088, PMCID: PMC5581791, DOI: 10.1007/s10815-017-0977-4.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Mullerian HormoneFemaleHumansOvarian FollicleOvulation InductionPolycystic Ovary SyndromeReproductionReproductive MedicineConceptsAnti-Müllerian hormonePolycystic ovarian syndromePotential therapeutic applicationsReproductive medicineOnset of menopauseNew potential therapeutic applicationsOvarian follicular developmentTherapeutic applicationsSpecific disease conditionsPromising therapeutic applicationOvarian syndromeOvulation inductionFertility preservationPharmacologic agentsFollicular developmentHormone analogueReproductive tractDisease conditionsTherapeutic usesTGF-beta superfamilyAntagonist functionImportant regulatorDiagnostic purposesGonadal tissueKey regulatorVitamin D Decreases Serum VEGF Correlating with Clinical Improvement in Vitamin D-Deficient Women with PCOS: A Randomized Placebo-Controlled Trial
Irani M, Seifer DB, Grazi RV, Irani S, Rosenwaks Z, Tal R. Vitamin D Decreases Serum VEGF Correlating with Clinical Improvement in Vitamin D-Deficient Women with PCOS: A Randomized Placebo-Controlled Trial. Nutrients 2017, 9: 334. PMID: 28350328, PMCID: PMC5409673, DOI: 10.3390/nu9040334.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeVascular endothelial growth factorOvarian hyperstimulation syndromeSerum VEGF levelsVitamin DVEGF levelsVitD supplementationVitD treatmentSeverity of OHSSSerum vascular endothelial growth factorRandomized placebo-controlled trialFerriman-Gallwey hirsutism scoreBeneficial effectsCharacteristic clinical abnormalitiesPlacebo-controlled trialVitamin D levelsVitamin D supplementationMultiple clinical parametersSignificant decreaseEndothelial growth factorD supplementationHirsutism scoreHyperstimulation syndromeVitD groupRandomized Placebo
2015
Vitamin D Supplementation Decreases TGF-β1 Bioavailability in PCOS: A Randomized Placebo-Controlled Trial
Irani M, Seifer DB, Grazi RV, Julka N, Bhatt D, Kalgi B, Irani S, Tal O, Lambert-Messerlian G, Tal R. Vitamin D Supplementation Decreases TGF-β1 Bioavailability in PCOS: A Randomized Placebo-Controlled Trial. The Journal Of Clinical Endocrinology & Metabolism 2015, 100: 4307-4314. PMID: 26485217, DOI: 10.1210/jc.2015-2580.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntigens, CDBiological AvailabilityCholecalciferolDehydroepiandrosterone SulfateEndoglinFemaleHumansInsulin ResistanceLipidsPolycystic Ovary SyndromeProspective StudiesReceptors, Cell SurfaceSocioeconomic FactorsTestosteroneTransforming Growth Factor beta1Vitamin DVitamin D DeficiencyVitaminsYoung AdultConceptsPolycystic ovary syndromeVD supplementationTGF-β1Clinical manifestationsClinical parametersAcademic-affiliated medical centerFerriman-Gallwey scoreOral vitamin D3Serum TGF-β1Soluble endoglin levelsPlacebo-controlled trialVitamin D supplementationTGF-β1 levelsNew treatment modalitiesD supplementationOral placeboRandomized PlaceboOvary syndromeVD levelsEndoglin levelsInsulin resistanceTreatment modalitiesMenstrual periodLipid profileVitamin D3The Emerging Role of Angiogenic Factor Dysregulation in the Pathogenesis of Polycystic Ovarian Syndrome
Tal R, Seifer DB, Arici A. The Emerging Role of Angiogenic Factor Dysregulation in the Pathogenesis of Polycystic Ovarian Syndrome. Seminars In Reproductive Medicine 2015, 33: 195-207. PMID: 26036901, DOI: 10.1055/s-0035-1552582.Peer-Reviewed Original ResearchConceptsPolycystic ovarian syndromeGrowth factorOvarian syndromePathophysiology of PCOSAngiogenic factor imbalanceOvarian hyperstimulation syndromeCommon endocrine disorderVascular endothelial growth factorPlatelet-derived growth factorBasic fibroblast growth factorMultiple angiogenic factorsEndothelial growth factorFibroblast growth factorHyperstimulation syndromeOvulatory dysfunctionStromal vascularityAnovulatory infertilityPolycystic ovariesEndocrine disordersReproductive ageTreatment strategiesFollicular growthOvarian angiogenesisAngiogenic factorsCorpus luteum
2014
Follicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulation
Tal R, Seifer DB, Grazi RV, Malter HE. Follicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulation. Reproductive Biology And Endocrinology 2014, 12: 82. PMID: 25141961, PMCID: PMC4150963, DOI: 10.1186/1477-7827-12-82.Peer-Reviewed Original ResearchMeSH KeywordsAdultCohort StudiesDown-RegulationFamily CharacteristicsFemaleFertilization in VitroFollicular FluidHumansInfertility, FemaleInfertility, MaleMaleNew York CityOocyte RetrievalOvarian ReserveOvulation InductionPlacenta Growth FactorPolycystic Ovary SyndromePregnancyPregnancy ProteinsPregnancy RateProspective StudiesUp-RegulationVascular Endothelial Growth Factor Receptor-1ConceptsNon-PCOS controlsPCOS womenOvarian stimulationSFlt-1 levelsAnti-Mullerian hormonePlacental growth factorVascular endothelial growth factorFollicular fluidOvarian syndromeSFlt-1Growth factorSoluble receptor sFlt-1BackgroundPolycystic ovarian syndromeControlled ovarian stimulationPlGF/sFltDay of hCGProspective cohort studyPolycystic ovarian syndromeNumber of oocytesEndothelial growth factorVEGF family membersCohort studyOocyte retrievalPlGF levelsVascular changesCharacterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes
Tal R, Seifer DB, Khanimov M, Malter HE, Grazi RV, Leader B. Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. American Journal Of Obstetrics And Gynecology 2014, 211: 59.e1-59.e8. PMID: 24593938, DOI: 10.1016/j.ajog.2014.02.026.Peer-Reviewed Original ResearchConceptsSerum antimüllerian hormone levelsAntimüllerian hormone levelsClinical pregnancy ratePopulation of womenAMH levelsPregnancy rateHormone levelsHigher clinical pregnancy rateElevated AMH levelsPresence of amenorrheaMultiple pregnancy rateOvarian hyperstimulation syndromeRetrospective cohort studyHigher AMH levelsPolycystic ovarian morphologyPolycystic ovarian syndromeSyndrome phenotypeReproductive technology outcomesHyperstimulation syndromePCOS severityClinical pregnancyOvarian stimulationTotal testosteroneCohort studyOvarian syndromeVitamin D Increases Serum Levels of the Soluble Receptor for Advanced Glycation End Products in Women With PCOS
Irani M, Minkoff H, Seifer DB, Merhi Z. Vitamin D Increases Serum Levels of the Soluble Receptor for Advanced Glycation End Products in Women With PCOS. The Journal Of Clinical Endocrinology & Metabolism 2014, 99: e886-e890. PMID: 24606102, DOI: 10.1210/jc.2013-4374.Peer-Reviewed Original ResearchConceptsAdvanced glycation end productsPolycystic ovary syndromeAnti-Mullerian hormoneSerum anti-Mullerian hormoneGlycation end productsVitamin DSerum sRAGED3 supplementationDeficient womenAMH concentrationsVit D3Soluble receptorDeposition of AGEsAbnormal ovarian folliculogenesisDihydroxyvitamin D3 supplementationSerum sRAGE levelsVit D3 supplementationVitamin D supplementationSerum AMH levelsVitamin D deficiencyBody mass indexD supplementationAMH levelsD deficiencySRAGE levels
2013
Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation
Tal R, Seifer DB, Shohat-Tal A, Grazi RV, Malter HE. Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation. Fertility And Sterility 2013, 100: 538-543. PMID: 23684116, DOI: 10.1016/j.fertnstert.2013.04.022.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntigens, CDCase-Control StudiesEndoglinFemaleFertilization in VitroFollicular FluidHumansInfertility, FemaleOvarian Hyperstimulation SyndromeOvulation InductionPolycystic Ovary SyndromeReceptors, Cell SurfaceSperm Injections, IntracytoplasmicTransforming Growth Factor beta1UltrasonographyYoung AdultConceptsPolycystic ovarian syndromeSerum soluble endoglinDay of hCGSoluble endoglinFollicular fluidTGF-β1Oocyte retrievalOvarian stimulationHCG administrationControl womenDay 3Pathogenesis of PCOSNon-PCOS control groupProspective case-control studyNon-PCOS controlsSerum TGF-β1Non-PCOS womenPolycystic ovary syndromeTGF-β1 levelsReproductive technology unitCase-control studyGrowth factor-β1Day of retrievalOvarian hyperstimulationOvarian syndrome
2008
Follicular-fluid neurotrophin levels in women undergoing assisted reproductive technology for different etiologies of infertility
Buyuk E, Seifer DB. Follicular-fluid neurotrophin levels in women undergoing assisted reproductive technology for different etiologies of infertility. Fertility And Sterility 2008, 90: 1611-1615. PMID: 18222435, DOI: 10.1016/j.fertnstert.2007.08.085.Peer-Reviewed Original ResearchConceptsMale factor infertilityDifferent etiologiesOvarian reserveNerve growth factorBDNF levelsNeurotrophin levelsBrain-derived neurotrophic factor levelsNT-3 concentrationNeurotrophic factor levelsProspective observational studyDiminished ovarian reserveHistory of endometriosisPolycystic ovarian syndromeIVF cyclesOvarian syndromeNGF levelsFollicular fluidNeurotrophin concentrationsObservational studyMAIN OUTCOMENGF concentrationsInfertilityFactor levelsEndometriosisEtiology
2007
Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance
Seifer DB, MacLaughlin DT. Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance. Fertility And Sterility 2007, 88: 539-546. PMID: 17559842, DOI: 10.1016/j.fertnstert.2007.02.014.Peer-Reviewed Original ResearchConceptsPolycystic ovarian diseaseMullerian Inhibiting SubstanceOvarian reserveOvulation inductionInhibiting SubstanceDiagnosis of PCODRisk of OHSSOvarian growth factorsWidespread clinical useOvarian hyperstimulationOvarian diseaseOvarian functionMEDLINE reviewClinical significanceIntracycle variabilityEarly markerClinical useConventional markersDiagnostic markerGrowth factorSpecific cutIntercycle variabilityDifferent assaysMarkersDiagnosis
2005
Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment
Fleming R, Harborne L, MacLaughlin DT, Ling D, Norman J, Sattar N, Seifer DB. Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertility And Sterility 2005, 83: 130-136. PMID: 15652898, DOI: 10.1016/j.fertnstert.2004.05.098.Peer-Reviewed Original ResearchMeSH KeywordsAdultAndrostenedioneAnti-Mullerian HormoneFemaleGlycoproteinsHumansHypoglycemic AgentsMetforminOvaryPolycystic Ovary SyndromeProspective StudiesTesticular HormonesConceptsPolycystic ovary syndromeDoses of metforminObese womenOvary syndromeMenstrual frequencyMetformin treatmentHormone changesReproductive hormone changesMonths of treatmentCohort of folliclesUniversity Teaching HospitalOvarian responseOvarian functionTeaching hospitalMAIN OUTCOMEMIS concentrationsProspective treatmentSubstance levelsMetforminMonthsWomenAssessment periodTreatmentSyndromeDoses